Drug Research
BMS obtains FDA approval for Opdivo as bladder cancer treatment
The US FDA has approved Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) as an adjuvant therapy for urothelial carcinoma (UC) patients at increased risk of recurrence following radical resection.
A programmed death-1 (PD-1) immune checkpoint inhibitor, Opdivo can specifically harness the...
Drug Research
McMaster, Sartorius Enter Biomanufacturing Partnership
Sartorius Stedim Biotech, an international partner of the biopharmaceutical industry, has entered into a partnership with McMaster University to improve manufacturing processes of antibody and virus-based treatments for diseases such as COVID-19, cancers and genetic disorders.
Using a state-of-the-art multi-column...
News
Clinerion patent for technology underpinning Patient Network Explorer is published
The new Clinerion patent underpins any medical EHR database infrastructure that incorporates a hybrid model of cloud-and-local server node installations at individual hospitals, as well as any method for search of patient cohort care metrics across such a platform....
Drug Research
SomaLogic and Twist Bioscience Corporation announce partnership to discover novel therapeutic targets and antibodies
CM Life Sciences II and SomaLogic, Inc., a leader in AI-data driven proteomics technology, and Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a collaboration...
Clinical Trials
Curevac’s CV2CoV Demonstrates Improved Immune Response And Protection In Preclinical Study
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, and GSK announced the publication of preclinical data investigating immune responses as well as the protective efficacy of CureVac’s first-generation vaccine...
Drug Research
Gritstone and CEPI Announce Agreement to Advance Second-Generation COVID-19 Vaccine Program Against SARS-CoV-2 Variants of Concern
Gritstone bio, Inc., a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, announced that the company entered into a funding agreement of up to $20.6 million with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance...
Drug Research
Exelixis and Invenra expand partnership to develop cancer antibodies
Exelixis and Invenra have extended their discovery and licensing partnership to include 20 more oncology targets for multi-specific antibodies, antibody-drug conjugates, and the development of other biologic candidates.
In May 2018, the companies collaborated to discover and develop mono-specific and...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read